Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: Chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine

BJU International

Volumn 93, Issue 9, 2004, Pages 1333-1338

  Van Brussel, J P ^a,c   Oomen, M A ^a   Vossebeld, P J M ^a   Wiemer, E A C ^a   Sonneveld, P ^a   Mickisch, G H J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Centrum für Operative Urologie Bremen   (Germany)

^c NONE   (Netherlands)

Author keywords

Buthionine sulfoximine; Chemosensitization; Chemotherapy; Glutathione; MK 571; Multidrug resistance associated protein; Zafirlukast

Indexed keywords

BUTHIONINE SULFOXIMINE; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MULTIDRUG RESISTANCE PROTEIN 1; TETRAZOLIUM; VERLUKAST; VINCRISTINE; ZAFIRLUKAST; ENZYME INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; PROPIONIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

ARTICLE; ASSAY; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; EXPERIMENTAL MODEL; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASUREMENT; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; DRUG RESISTANCE; FLOW CYTOMETRY; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BLOTTING, WESTERN; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROPIONATES; PROSTATIC NEOPLASMS; QUINOLINES;

EID: 2942744800     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04847.x     Document Type: Article

References (24)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-109
2. van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Muller M, Vellenga E. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 1998; 4: 1727-36
3. Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 1988; 241: 694-7
4. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998; 4: 1393-403
5. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35: 664-71
6. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C et al. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001; 165: 130-5
7. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990; 2: 15-22
8. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17: 16-23
9. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21: 274-81
10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5
11. Zijlstra JG, de Vries EG, Mulder NH. Multifactohal drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1987; 47: 1780-4
12. Dalton WS, Grogan TM, Rybski JA et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747-52
13. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro. Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. The Prostate 1988; 12: 99-110
14. Armitage P, Berry G. Statistical Methods in Medical Science, 2nd edn. Oxford: Blackwell Scientific Publications, 1987
15. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427
16. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-61
17. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Prac Natl Acad Sci USA 1994; 91: 3497-504
18. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999; 1461: 359-76
19. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302
20. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664-71
21. Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996; 271: 9675-82
22. Krell RD, Aharony D, Buckner CK et al. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990; 141: 978-87
23. Depre M, Margolskee DJ, Hsieh JY et al. Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man. Eur J Clin Pharmacol 1992; 43: 427-30
24. O'Dwyer PJ, Hamilton TC, LaCreta FP et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-56